Power Law company profile

Akeso Biopharma

Biotech & Life Sciences · Zhongshan, China · Founded 2012 · IPO 2020 Decacorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$15B

Market cap · Apr/2026

Revenue

$292M

Latest reported FY

Investors

4 investors on Akeso Biopharma's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 4 investors entered at this stage

ShenZhen GTJA Investment Group

Loyal Valley Capital

Sino Biopharmaceutical

Ally Bridge Group

Global footprint

Where Akeso Biopharma has talent and traffic

AI talent share

0.9% of workforce is AI talent
(1 of 112 staff)

Core AI00%

Other AI10.89%

Non-AI workforce11199.11%

Web traffic by country

27K monthly visits
across markets

🇺🇸 United States42.2%

🇨🇳 China38.9%

🇭🇰 Hong Kong7.4%

🇬🇧 United Kingdom4.8%

🇮🇳 India3.7%

Top 5 markets shown

Patent intelligence

$59M patent portfolio · 102 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$59M

0.40% of market cap · 13.1× smaller than top peer BioNTech ($780M)

102 active patent families

Where Akeso Biopharma innovates Molecular biologyPharmaceutical drugAntiendomysial antibodiesHeavy chainAcid amino sequences

Tracks the peer median across all five Patsnap quality dimensions.

Quality vs same-sector peers

Akeso Biopharma on the five Patsnap quality dimensions

Akeso Biopharma in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Akeso Biopharma concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Akeso Biopharma and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Akeso Biopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo